Vardenafil, as a potent selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), requires rigorous chiral synthesis protocols. Our technical roadmap focuses on catalytic hydrogenation and optimized crystallization processes to achieve pharmaceutical-grade purity (≥99.5%). We are moving toward "Continuous Flow Chemistry" to reduce impurity profiles, ensuring superior clinical outcomes.
Leveraging Industry 4.0, our manufacturing plants integrate AI-driven process control systems. By digitizing our supply chain, we offer unmatched transparency from raw material sourcing (API intermediates) to final batch release, ensuring that global OEM partners experience zero volatility in volume or quality.
We operate strictly under cGMP guidelines. Our Vardenafil production is backed by comprehensive DMF documentation, enabling seamless regulatory filing in the US, EU, and emerging markets.
With operational hubs in Mexico and South Africa, we bridge the gap between Chinese manufacturing efficiency and local regulatory/logistical compliance requirements.
For multinational corporations, we provide a "One-Stop API Solution," minimizing the complexity of dealing with fragmented supply chains through our proprietary procurement platform.
Q: What is the lead time for OEM Vardenafil orders?
A: With our scaled production lines, we maintain a robust inventory of intermediates, allowing for a standard 4-6 week production lead time depending on order volume.
Q: How do you ensure product purity?
A: Every batch undergoes rigorous HPLC and GC-MS testing. We provide a full Certificate of Analysis (CoA) with every shipment to ensure compliance with pharmacopeial standards (USP/EP).
